CoChat

Effect of Exenatide on the Steady‐State Pharmacokinetics of Digoxin

The DOI matches its Crossref record; 12 of the 13 references it cites were found in a registry or an index.

Abstract

This open‐label study investigated the effect of exenatide coadministration on the steady‐state plasma pharmacokinetics of digoxin. A total of 21 healthy male subjects received digoxin (day 1, 0.5 mg twice daily; days 2–12, 0.25 mg once daily) and exenatide (days 8–12, 10 μg twice daily). Digoxin plasma and urine concentrations were measured on days 7 and 12. Exenatide coadministration did not change the overall 24‐hour steady‐state digoxin exposure (AUC τ,ss) and C min,ss but caused a 17% decrease in mean plasma digoxin C max,ss (1.40 to 1.16 ng/mL) and an increase in digoxin t max,ss (median increase, 2.5 hours). Although the decrease in digoxin C max,ss was statistically significant, peak concentrations were within the therapeutic concentration range in all subjects. Digoxin urinary pharmacokinetic parameters were not altered. Gastrointestinal symptoms, the most common adverse effects of exenatide, decreased over time. Exenatide administration does not cause any changes in digoxin steady‐state pharmacokinetics that would be expected to have clinical sequelae; thus, dosage adjustment does not appear warranted, based on pharmacokinetic considerations.

Overview

Integrity signals

Registry

Crossref · 10.1177/0091270005278806

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 12 references

Research works printed but not linked: 2

  1. Kendall DM, 2004, Effects of exenatide (exendin‐4) on glycemic control and weight over 30 weeks in patients with type 2 diabetes mellitus treated with metformin and a sulfonylurea, Diabetologia, 47, A279
  2. 2003, Physician's Desk Reference, 1579

Cited by

See all 69

Metadata

Authors
Kothare, P. A., Soon, D. K. W., Linnebjerg, H., Park, S., Chan, C., Yeo, A., Lim, M., Mace, K. F., & Wise, S. D.
Affiliations
  • Eli Lilly (United States) (US)
  • National University of Singapore (SG)
  • Eli Lilly (United Kingdom) (GB)
Corresponding author
Kothare, Prajakti A.
Venue
The Journal of Clinical Pharmacology
Publisher
Wiley
Published
2005-09
Volume
45
Issue
9
Pages
1032-1037
ISSN
  • 0021-9754 (ISSN-L)
  • 0091-2700
  • 1552-4604
OpenAlex
W1976367840
Cited by
69
References
13
Citations by year
2026: 1 · 2025: 4 · 2024: 2 · 2020: 1 · 2019: 3 · 2018: 4 · 2017: 3 · 2016: 2 · 2015: 3 · 2014: 3 · 2013: 2 · 2012: 4
FWCI
5.37
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Keywords
exenatide, digoxin, drug-drug interactions, steady-state pharmacokinetics, Cmax, Tmax, urinary excretion, gastrointestinal adverse effects, dose adjustment, GLP-1 receptor agonists
MeSH terms
Exenatide, Adult, Anti-Arrhythmia Agents, Cardiotonic Agents, Digoxin, Drug Interactions, Humans, Male, Nausea, Peptides, Venoms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Exenatide on the Steady‐State Pharmacokinetics of Digoxin. https://app.cochat.ai/papers/10.1177/0091270005278806
The paper
Kothare, P. A., Soon, D. K. W., Linnebjerg, H., Park, S., Chan, C., Yeo, A., Lim, M., Mace, K. F., & Wise, S. D. (2005). Effect of Exenatide on the Steady‐State Pharmacokinetics of Digoxin. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270005278806

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.